Skip to main content
SpringerLink
Log in

Cognitive dysfunction is a considerable, yet under-recognised, problem in patients with multiple sclerosis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lyseng-Williamson KA, Plosker GL. Management of relapsing-remitting multiple sclerosis: defining the role of subcutaneous recombinant interferon-b-1a (Rebif). Dis Manage Health Outcomes 2002; 10(5): 307–25

    Article  CAS  Google Scholar 

  2. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs 2002; 16(7): 445–55

    Article  PubMed  Google Scholar 

  3. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis: Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48(6): 885–92

    Article  PubMed  CAS  Google Scholar 

  4. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53(8): 1698–704

    Article  PubMed  CAS  Google Scholar 

  5. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47(6): 1463–8

    Article  PubMed  CAS  Google Scholar 

  6. Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56(3): 319–24

    Article  PubMed  CAS  Google Scholar 

  7. Khan O, Zabad R, Caon C, et al. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16(8): 563–78

    Article  PubMed  CAS  Google Scholar 

  8. Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995; 8(3): 216–20

    Article  PubMed  CAS  Google Scholar 

  9. Rao SM, Leo GL, Ellington L, et al. Cognitive dysfunction in multiple sclerosis: II: impact on employment and social functioning. Neurology 1991; 41(5): 692–6

    Article  PubMed  CAS  Google Scholar 

  10. Amato MP, Ponziani G, Siracusa G, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58(10): 1602–6

    Article  PubMed  CAS  Google Scholar 

  11. Greene YM, Tariot PN, Wishard H, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20(3): 350–6

    Article  PubMed  CAS  Google Scholar 

  12. Rorie KD, Stump DA, Jeffrey DR. Effects of donepezil on cognitive function in patients with multiple sclerosis [abstract]. Neurology 2001; 56 Suppl. 3: A99

    Google Scholar 

  13. Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. Arch Neurol 1988; 45(4): 435–7

    Article  PubMed  CAS  Google Scholar 

  14. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol 1990; 47(1): 98–104

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cognitive dysfunction is a considerable, yet under-recognised, problem in patients with multiple sclerosis. Drugs Ther. Perspect 19, 13–16 (2003). https://doi.org/10.2165/00042310-200319050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319050-00005

Keywords

Search

Navigation